Clinical Report: Correction to a Selective EGFR and PI3K Inhibitor Study

Overview

The Nature Cancer author correction, published online July 11, 2024, reports a clerical error in Fig. 6b and its associated source data file. Three mouse-serum insulin ELISA measurements were inadvertently duplicated during transfer from the original plate-reader data file. Fig. 6b and the source data file were amended to represent the full set of original measurements from samples obtained from six mice.

Background

The corrected article concerns MTX-531, described in the related context as a preclinical, first-in-class selective dual EGFR and PI3K inhibitor designed to target adaptive resistance. EGFR-TKI resistance can involve bypass and downstream signaling, including the PI3K/AKT/mTOR pathway. The correction is limited to the presentation of insulin ELISA measurements in Fig. 6b and its source data file. The supplied context does not report a change to the study’s broader findings.

Data Highlights

Key Findings

• The Nature Cancer author correction was published online July 11, 2024.
• A clerical error during transfer of mouse-serum insulin ELISA values resulted in three measurements being duplicated.
• The affected material was Fig. 6b and its associated source data file.
• The experiment used samples obtained from six mice.
• Fig. 6b and the source data file were amended to represent the full set of original measurements.

Clinical Implications

The correction concerns the presentation of mouse-serum insulin ELISA measurements in Fig. 6b and its associated source data file. The supplied correction text does not report clinical efficacy or safety findings or make a clinical recommendation.

Conclusion

The Nature Cancer author correction reports that three mouse-serum insulin ELISA measurements were inadvertently duplicated in Fig. 6b and its associated source data file. Both were amended to represent the full set of original measurements from samples obtained from six mice.

Related Resources & Content

1. Nature Cancer, 2024 — Author Correction: A First-in-Class Selective EGFR and PI3K Inhibitor Enables Single-Molecule Targeting of Adaptive Resistance
2. ASCO Publications, 2024 — Erratum: Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
3. Nature Reviews Clinical Oncology, 2025 — Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4. ASCO Publications — Light-activated EGFR antibody–drug conjugate: Analysis of selectivity and translational profile for first-in-human evaluation.
5. ASCO Publications — Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors: A perspective study in NSCLC patients using targeted next generation sequencing.
6. ASCO Publications — Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors: A perspective study in NSCLC patients using targeted next generation sequencing.
7. Nature Cancer author correction
8. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
9. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 | Journal of Clinical Oncology